ADMA Biologics (ADMA) to Release Quarterly Earnings on Monday

ADMA Biologics (NASDAQ:ADMA) is expected to release its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect ADMA Biologics to post earnings of $0.20 per share and revenue of $139.80 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $16.10 on Monday. The company has a market capitalization of $3.83 billion, a PE ratio of 18.72 and a beta of 0.49. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18. The stock’s 50 day moving average price is $17.62 and its 200-day moving average price is $16.84. ADMA Biologics has a twelve month low of $13.50 and a twelve month high of $25.67.

Institutional Investors Weigh In On ADMA Biologics

Large investors have recently modified their holdings of the stock. Lido Advisors LLC lifted its stake in ADMA Biologics by 3.8% in the fourth quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company’s stock valued at $312,000 after purchasing an additional 629 shares during the last quarter. Cim LLC increased its position in ADMA Biologics by 0.7% in the third quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock worth $1,341,000 after buying an additional 665 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of ADMA Biologics by 28.9% in the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 700 shares during the period. Cerity Partners LLC lifted its position in shares of ADMA Biologics by 1.8% during the 2nd quarter. Cerity Partners LLC now owns 48,572 shares of the biotechnology company’s stock valued at $884,000 after buying an additional 869 shares during the last quarter. Finally, Fieldview Capital Management LLC lifted its position in shares of ADMA Biologics by 7.3% during the 4th quarter. Fieldview Capital Management LLC now owns 21,708 shares of the biotechnology company’s stock valued at $396,000 after buying an additional 1,486 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, ADMA Biologics presently has a consensus rating of “Buy” and a consensus price target of $28.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.